Mostrar el registro sencillo del ítem

Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial

dc.rights.licenseopenen_US
hal.structure.identifierHôpital Haut-Lévêque [CHU Bordeaux]
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorGATTA-CHERIFI, Blandine
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorMOHAMMEDI, Kamel
hal.structure.identifierCentre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
dc.contributor.authorCARIOU, Tanguy
hal.structure.identifierCHU Pitié-Salpêtrière [AP-HP]
hal.structure.identifierNutrition et obésités: approches systémiques (UMR-S 1269) [Nutriomics]
hal.structure.identifierCentre de Référence du Syndrome de Prader-Willi [CHU Toulouse] [SPW-PRADORT]
dc.contributor.authorPOITOU, Christine
hal.structure.identifierCHU Pitié-Salpêtrière [AP-HP]
dc.contributor.authorTOURAINE, Philippe
hal.structure.identifierHospices Civils de Lyon [HCL]
dc.contributor.authorRAVEROT, Gerald
hal.structure.identifierMarseille medical genetics - Centre de génétique médicale de Marseille [MMG]
hal.structure.identifierInstitut Marseille Maladies Rares [MarMaRa]
hal.structure.identifierService d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM]
dc.contributor.authorBRUE, Thierry
hal.structure.identifierPhysiologie et physiopathologie endocriniennes [PHYSENDO]
hal.structure.identifierAP-HP. Université Paris Saclay
hal.structure.identifierHôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
hal.structure.identifierUniversité Paris-Saclay
dc.contributor.authorCHANSON, Philippe
hal.structure.identifierMitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale [MITOVASC]
hal.structure.identifierEuropean Reference Network on rare endocrine conditions [Endo-ERN]
hal.structure.identifierCentre Hospitalier Universitaire d'Angers [CHU Angers]
dc.contributor.authorILLOUZ, Frédéric
hal.structure.identifierService Endocrinologie, maladies métaboliques et nutrition [CHU Toulouse]
dc.contributor.authorGRUNENWALD, Solange
hal.structure.identifierCentre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
dc.contributor.authorCHABRE, Olivier
hal.structure.identifierHôpital de la Cavale Blanche
dc.contributor.authorSONNET, Emmanuel
hal.structure.identifierMarseille medical genetics - Centre de génétique médicale de Marseille [MMG]
hal.structure.identifierInstitut Marseille Maladies Rares [MarMaRa]
hal.structure.identifierLaboratoire de Biochimie et de Biologie Moléculaire [Hôpital de la Conception - APHM]
dc.contributor.authorCUNY, Thomas
hal.structure.identifierInstitut Cochin [IC UM3 (UMR 8104 / U1016)]
hal.structure.identifierHôpital Cochin [AP-HP]
dc.contributor.authorBERTHERAT, Jerôme
hal.structure.identifierHôpital Européen Georges Pompidou [APHP] [HEGP]
dc.contributor.authorCZERNICHOW, Sébastien
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorFRISON, Eric
hal.structure.identifierHôpital Haut-Lévêque [CHU Bordeaux]
dc.contributor.authorTABARIN, Antoine
dc.date.accessioned2025-04-24T07:01:52Z
dc.date.available2025-04-24T07:01:52Z
dc.date.issued2024-04-30
dc.identifier.issn0804-4643en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206380
dc.description.abstractEnAbstract Importance A major issue in the management of craniopharyngioma-related obesity (CRO) is the ineffectiveness of the current therapeutic approaches. Objective To study the efficacy of glucagon-like peptide-1 analogs compared with placebo in adults with obesity CRO. Design A double-blind multicenter superiority randomized clinical in trial in two parallel arms. Setting Eleven French University Hospital Centers. Participants Adults with CRO (body mass index > 30 kg/m²) without the sign of recurrence of craniopharyngioma in the past year. Interventions Exenatide or placebo injected subcutaneously twice a day during 26 weeks. Main Outcomes and Measures The primary outcome was the mean change in body weight at week 26 in the intention-to-treat population. Secondary outcomes were eating behavior, calories intake, energy expenditure, cardiovascular, metabolic risk factor, quality of life, and the tolerance profile. Results At week 26, weight decreased from baseline by a mean of −3.8 (SD 4.3) kg for exenatide and −1.6 (3.8) kg for placebo. The adjusted mean treatment difference was −3.1 kg (95% confidence interval [CI] −7.0 to 0.7, P = 0.11). Results were compatible with a higher reduction of hunger score with exenatide compared with placebo (estimated treatment difference in change from baseline to week 26: −2.3, 95% CI −4.5 to −0.2), while all other outcomes did not significantly differ between groups. Adverse events were more common with exenatide versus placebo, and occurred in, respectively, 19 (95%) participants (108 events) and 14 (70%) participants (54 events). Conclusions and Relevance Combined with intensive lifestyle interventions, a 26-week treatment with exenatide was not demonstrated superior to placebo to treat craniopharyngioma-related obesity.
dc.language.isoENen_US
dc.subject.enhypothalamic obesity
dc.subject.encraniopharyngioma
dc.subject.englucagon-like peptide-1 analogs
dc.subject.enlifestyle intervention
dc.title.enImpact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/ejendo/lvae024en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Endocrinologie et métabolismeen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed38450721en_US
bordeaux.journalEuropean Journal of Endocrinologyen_US
bordeaux.page257-265en_US
bordeaux.volume190en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-04867934
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Journal%20of%20Endocrinology&rft.date=2024-04-30&rft.volume=190&rft.issue=4&rft.spage=257-265&rft.epage=257-265&rft.eissn=0804-4643&rft.issn=0804-4643&rft.au=GATTA-CHERIFI,%20Blandine&MOHAMMEDI,%20Kamel&CARIOU,%20Tanguy&POITOU,%20Christine&TOURAINE,%20Philippe&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem